Doxorubicin-Transdrug in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.

Trial Profile

Doxorubicin-Transdrug in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Antineoplastics; Doxorubicin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms DOTAHCC1
  • Sponsors BioAlliance Pharma
  • Most Recent Events

    • 11 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
    • 11 Aug 2014 Status changed from suspended to completed as reported by European Clinical Trials Database record.
    • 06 Sep 2011 Preliminary results of 28 evaluable patients (of a planned 50) were presented at the annual congress of the International Liver Cancer Association, as reported in a BioAlliance Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top